AstraZeneca/Cellartis To Use Human Embryonic Stem Cells For Predictive Toxicology
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. firm looks to increase safety, avoid expensive late-stage failures with preclinical screening on real human liver and heart muscle tissue.
You may also be interested in...
France's Cellectis To Acquire Cellartis To Produce A Leader In Stem Cell Technologies
The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.
France's Cellectis To Acquire Cellartis To Produce A Leader In Stem Cell Technologies
The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.
iZumi & Pierian Join Forces to Advance EMerging iPS Cell Platform
Every so often an undeniably important technology emerges resulting in the consolidation of IP and the alignment of thought leaders around a few main players. The new battleground is stem cells. And though the two heavy hitters in the promising induced pluripotent stem (iPS) cell space, Ipierian and Fate Therapeutics, are perhaps less aggressive in publicly asserting their dominance, they've positioned themselves as leading competitors in the still-nascent but rapidly advancing area of cellular reprogramming.